Journal
CHILDREN-BASEL
Volume 8, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/children8070607
Keywords
COVID-19 vaccine; myocarditis; pericarditis
Categories
Ask authors/readers for more resources
This cross-sectional study of 29 cases of acute myopericarditis following COVID-19 mRNA vaccination found that chest pain was the most common symptom, occurring within 1-5 days. All patients had elevated troponin levels, with most recovering within 1-3 weeks. Treatment mainly involved non-steroidal anti-inflammatory drugs, with some patients receiving intravenous immune globulin and corticosteroids.
This is a cross-sectional study of 29 published cases of acute myopericarditis following COVID-19 mRNA vaccination. The most common presentation was chest pain within 1-5 days after the second dose of mRNA COVID-19 vaccination. All patients had an elevated troponin. Cardiac magnetic resonance imaging revealed late gadolinium enhancement consistent with myocarditis in 69% of cases. All patients recovered clinically rapidly within 1-3 weeks. Most patients were treated with non-steroidal anti-inflammatory drugs for symptomatic relief, and 4 received intravenous immune globulin and corticosteroids. We speculate a possible causal relationship between vaccine administration and myocarditis. The data from our analysis confirms that all myocarditis and pericarditis cases are mild and resolve within a few days to few weeks. The bottom line is that the risk of cardiac complications among children and adults due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection far exceeds the minimal and rare risks of vaccination-related transient myocardial or pericardial inflammation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available